Dechra Pharmaceuticals Gestione
Gestione criteri di controllo 4/4
Dechra Pharmaceuticals Il CEO è Ian Page, nominato in Nov2001, e ha un mandato di 22.17 anni. la retribuzione annua totale è £ 1.04M, composta da 59.9% di stipendio e 40.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.36% delle azioni della società, per un valore di £ 15.64M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 4.3 anni.
Informazioni chiave
Ian Page
Amministratore delegato
UK£1.0m
Compenso totale
| Percentuale dello stipendio del CEO | 59.9% |
| Mandato del CEO | 22.2yrs |
| Proprietà del CEO | 0.4% |
| Durata media del management | 4.8yrs |
| Durata media del Consiglio di amministrazione | 4.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2023 | UK£1m | UK£621k | -UK£28m |
| Mar 31 2023 | n/a | n/a | UK£6m |
| Dec 31 2022 | n/a | n/a | UK£40m |
| Sep 30 2022 | n/a | n/a | UK£49m |
| Jun 30 2022 | UK£2m | UK£597k | UK£58m |
| Mar 31 2022 | n/a | n/a | UK£66m |
| Dec 31 2021 | n/a | n/a | UK£73m |
| Sep 30 2021 | n/a | n/a | UK£64m |
| Jun 30 2021 | UK£3m | UK£551k | UK£56m |
| Mar 31 2021 | n/a | n/a | UK£50m |
| Dec 31 2020 | n/a | n/a | UK£44m |
| Sep 30 2020 | n/a | n/a | UK£39m |
| Jun 30 2020 | UK£2m | UK£517k | UK£34m |
| Mar 31 2020 | n/a | n/a | UK£31m |
| Dec 31 2019 | n/a | n/a | UK£29m |
| Sep 30 2019 | n/a | n/a | UK£30m |
| Jun 30 2019 | UK£3m | UK£500k | UK£31m |
| Mar 31 2019 | n/a | n/a | UK£28m |
| Dec 31 2018 | n/a | n/a | UK£25m |
| Sep 30 2018 | n/a | n/a | UK£30m |
| Jun 30 2018 | UK£3m | UK£500k | UK£36m |
| Mar 31 2018 | n/a | n/a | UK£40m |
| Dec 31 2017 | n/a | n/a | UK£43m |
| Sep 30 2017 | n/a | n/a | UK£35m |
| Jun 30 2017 | UK£3m | UK£490k | UK£26m |
Compensazione vs Mercato: La retribuzione totale di Ian ($USD 1.31M ) è inferiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 3.22M ).
Compensazione vs guadagni: La retribuzione di Ian è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Ian Page (62 yo)
22.2yrs
Mandato
UK£1,037,000
Compensazione
Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, MD & Executive Director | 22.2yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.8yrs | UK£641.00k | 0.010% £ 452.7k | |
| Chief Scientific Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Chief Information Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Chief People Officer | no data | Nessun dato | Nessun dato | |
| President of North America | no data | Nessun dato | Nessun dato | |
| Company Secretary | 6.5yrs | Nessun dato | Nessun dato |
4.8yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di DPH è considerato esperto (durata media dell'incarico 4.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, MD & Executive Director | 26.6yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.3yrs | UK£641.00k | 0.010% £ 452.7k | |
| Independent Non-Executive Director | less than a year | UK£36.00k | Nessun dato | |
| Senior Independent Director | 7.1yrs | UK£107.00k | 0.0052% £ 227.2k | |
| Independent Non-Executive Chairman | 3.8yrs | UK£207.00k | 0.0033% £ 143.6k | |
| Designated Non-Executive Director | 4.9yrs | UK£72.00k | 0.0012% £ 53.3k | |
| Independent Non-Executive Director | 1.6yrs | UK£73.00k | 0.00053% £ 23.3k |
4.3yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DPH sono considerati esperti (durata media dell'incarico 4.3 anni).